RLAY: Multiplikator rega marang pendapatan Relay Therapeutics Inc

Relay Therapeutics (RLAY) optimizes innovation by outsourcing production and testing to third-party contractors. The price/sales ratio trend on the GURU.Markets website shows a peak, but 382.30 represents the current metric value. However, AI development carries risks of trial failures and high costs. Stable management with deep scientific expertise and liquidity mitigates these challenges, ensuring the development of targeted therapy.

RLAY Kapitalisasi marang pendapatan Relay Corp (04.07.2022 - 13.11.2026)

Rincian analitis perusahaan Relay Pharma (RLAY)

- rega saham lan konsensus proyeksi valuasi:

Bagan owah-owahan rega relaytx.com|RLAY - Prakiraan konsensus analis

- informasi kapitalisasi pasar:

Kapitalisasi pasar Relay Pharma|RLAY - Nilai Perusahaan

- data kapitalisasi buku:

Nilai Aset Bersih saben Saham Relay Therapeutics|RLAY - Aset Bersih Perusahaan|Multiplikator Kapitalisasi Pasar marang Nilai Buku relaytx.com|RLAY - Total Aset Perusahaan

- statistik kawajiban utang lan likuiditas:

- data bathi lan kelipatan valuasi:

RLAY - Bathi resik|Bathi resik sing dikarepake Relay Therapeutics|RLAY - Rasio rega marang bathi|Pangali mangsa ngarep rega marang bathi Relay Therapeutics Inc|RLAY - Pangali PEG|Pangali EV/EBITDA Relay Pharma|RLAY - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben siji saham sajrone 12 wulan pungkasan Relay Therapeutics|RLAY - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan relaytx.com|RLAY - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Relay Therapeutics

- indikator pendapatan dodolan lan penghasilan bisnis:

RLAY - Pendapatan lan volume dodolan|Volume dodolan sing dikarepake perusahaan relaytx.com|RLAY - Rasio rega marang pendapatan|Rasio rega marang prakiraan pendapatan Relay Pharma

Ringkesan analitik perusahaan:relaytx.com, RLAY

The competitiveness of Relay Therapeutics (RLAY) is based on the precision of the Dynamo platform, making the price-to-sales ratio a key indicator of market expectations for future successes in oncology biotech. This ratio correlates the total business value with its actual revenue, allowing investors to assess the premium paid for clinical trial potential and partnerships with Roche relative to current cash flows.

Karo sapa Relay Therapeutics saingan

GMAB (genmab.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S EXEL (Exelixis)|Multiplikator rega marang pendapatan Nuvalent Inc|Kymera Therapeutics Inc - Multiplikator P/S|Rega marang dodolan IDEAYA Corp|ELVN (Enliven Therapeutics) - Kapitalisasi marang pendapatan|ORIC: Kapitalisasi marang volume dodolan|NRIX (Nurix Therapeutics, Inc.) - Multiplikator P/S|Rega marang dodolan Tyra Biosciences Inc TYRA|Multiplikator P/S VSTM|Monte Rosa Corp - Rasio kapitalisasi marang pendapatan|Cullinan Therapeutics - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IMRX|CCCC: Kapitalisasi marang pendapatan|Black Diamond Therapeutics, Inc. - Kapitalisasi marang volume dodolan|RPTX: Multiplikator P/S|PMV Pharmaceuticals, Inc - Rasio kapitalisasi pasar marang pendapatan|KPTI (Karyopharm Therapeutics, Inc.) - Multiplikator P/S|Rega marang dodolan Propanc Biopharma, Inc. PPCB|Rasio rega marang pendapatan Bio Green Med Solution (BGMS)|AADI (aadibio.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ALRN (Aileron Therapeutics, Inc.)|Multiplikator P/S Blueprint Medicines Corp. BPMC|GLYC - Rasio rega marang pendapatan|Rasio rega marang dodolan SWTX